Vise Technologies Inc. Buys Shares of 85,930 Merck & Co., Inc. $MRK

Vise Technologies Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 85,930 shares of the company’s stock, valued at approximately $6,802,000.

Several other institutional investors have also modified their holdings of the business. Little House Capital LLC lifted its position in Merck & Co., Inc. by 1.2% in the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after acquiring an additional 308 shares in the last quarter. Semus Wealth Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after purchasing an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC lifted its holdings in shares of Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock valued at $1,739,000 after purchasing an additional 3,282 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its position in shares of Merck & Co., Inc. by 9.8% during the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after buying an additional 79,529 shares during the period. Finally, Amplius Wealth Advisors LLC grew its holdings in shares of Merck & Co., Inc. by 117.4% during the second quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock worth $488,000 after buying an additional 3,329 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares of the company’s stock, valued at $2,054,475.02. The trade was a 25.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MRK shares. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their target price for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $104.47.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $86.34 on Monday. The firm has a market capitalization of $214.30 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $84.59 and its two-hundred day moving average price is $82.08. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. The company had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.